Finance

Results: 433-444 of 49886

New NHS blood test trial to help spot cancers earlier

ACCESSIWAY ACQUIRES SUBLY TO BECOME A SINGLE PARTNER FOR WEB, MOBILE AND MULTIMEDIA ACCESSIBILITY

PR Newswire associated0

"Taiwan Weeks 2026" Opens as Taiwan Strengthens Global Capital Market Connectivity

ENERGY GRID RISKS BEING OVERWHELMED BY 2035 UNLESS CONSUMERS SEE THE BENEFIT OF SHIFTING THEIR ENERGY USE, WARNS USWITCH CEO

PR Newswire associated0

Goldie & Frenchie Surpass 1.5 Billion Views, Emerging as Two of the World's Most Popular AI Characters

By working capital measures, the 1,000 largest European public companies had a good year. The Hackett Group’s 2026 European Working Capital Survey found the average cash conversion cycle (CCC) improved by 1.8 days (4%) to 44.8 days. Days sales outstanding (DSO) fell by 1.9 days (4%) to 47.4 days, while days inventory outstanding (DIO) declined by 3.3 days (5%) to 67.3 days. Days payable outstanding (DPO) moved in the other direction, falling 3.3 days (5%) to 69.8 days to return part of the gain. The broader picture was weaker. Revenue for Europe’s top 1,000 firms rose just 0.8% compared to 6% in North America. Operating cash flow fell 3% to 13% of revenue and earnings before interest, taxes, depreciation and amortization (EBITDA) dropped 2% to 17%. The average cash-to-current liability ratio slipped 1% to 29%. Debt as a share of revenue improved 1% to 47%, though leverage remains 13% higher than three years ago.

The Hackett Group® Study Finds €1.26 Trillion Remains Trapped in Working Capital Across Europe’s Largest Companies

PR Newswire associated0

HEXCLAD BRINGS CATEGORY-DEFINING INNOVATION TO THE WINE CHILLER

BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J.

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations

Store front of HOCHO KNIFE

Beyond Kobe Beef and Sake: HOCHO KNIFE (Import Japan.com) Opens Its First Japanese Knife Store in Kobe

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026